A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Summary

This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of MEDI9447 in Japanese patients with advanced solid malignancies.This study consists of 2 cohorts. Cohort 1 (dose level 1) and Cohort 2 (dose level 2). At least 3 or up to 6 evaluable Japanese patients with advanced solid malignancies will be enrolled in each cohort.

Timeline

Start

2018-11-07

Primary completion

2019-06-19

Completion

2019-06-19

Drugs

Indications